Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: StockDoc who wrote (14161)	7/18/2000 1:51:25 PM
From: Bluegreen	Read Replies (1) \| Respond to of 17367

Maybe someday people might see the importance of rapid and effective killing of gram neg bugs in order to prevent FULL BLOWN sepsis in the first place. I see great need for people who are hospitalized on the cusp of sepsis secondary to gram neg infections. All clinicians can really offer are conventional antibiotics. Common practice is to ramp up doses of Vanco or Genta if bugs are not cooperative. You might want to investigate the costs secondary to high doses of Vancomycin and Gentamycin. I need not remind you of costs associated with damage to liver, eyes, ears and kidneys secondary to high doses of these conventional antibiotics. Also day by day the bugs just keep getting more and more uncooperative. Yes indeed I see a GREAT need for a rapid and effective killer of gram neg bugs and just think if doses of Genta and Vanco could be lowered overall. If one could just find a safe product to use in synergy with conventional antibiotics. In my opinion Xoma has done a horrible job of picking trials for Neuprex, hopefully Baxter will do better. BTW, in regards to LLY sepsis trial. As I understand it the endpoint was mortality? If that is the case, what neuro and limb wise state were these patients in after saved from death???? Wouldn't it be great if you could add a product to Protein C that was safe and made it more effective and safer???